Company intelligence / Profile preview

Shanghai Xinzhi BioMed

Shanghai, Shanghai, China

Ownership: Private
Development stage: Other

Overview

The company’s BBM-H901 (dalnacogene ponparvovec) is the first hemophilia B gene therapy approved in China, with positive clinical results published in The Lancet Haematology and New England Journal of Medicine. Programs in DMD and osteoarthritis are in the IND or early clinical stage, with several candidates progressing through regulatory review.

Therapeutic areas: HematologyRheumatologyRare Diseases
Modalities: Gene therapyViral vector (AAV-based)
Industry: Biotech

Partnerships

AskBio (strategic gene therapy R&D and commercialization partnership)ThermoFisher (strategic cooperation in gene therapy R&D/manufacturing)Takeda China (exclusive commercialization partnership for Hemophilia B in China)

Beyond the preview

Go deeper on Shanghai Xinzhi BioMed.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanghai Xinzhi BioMed.

Explore the full profile